UroGen Pharma (URGN) Cash from Operations (2017 - 2026)

UroGen Pharma (URGN) has 10 years of Cash from Operations data on file, last reported at 45316000.0 in Q1 2026.

• Quarterly Cash from Operations fell 7.83% year-over-year to 45316000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 165736000.0 (down 54.81% YoY) and the FY2025 annual result came in at 162444000.0, down 67.87% from the prior year.
• Cash from Operations slipped to 45316000.0 in Q1 2026, from 38325000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 12996000.0 in Q4 2023 to a low of 45316000.0 in Q1 2026.
• A 5-year average of 27556529.41 and a median of 24199000.0 in 2022 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2023 — Cash from Operations soared 40.25% — and 2025, when it sank 181.41%.
• Tracing URGN's Cash from Operations over 5 years: stood at 21752000.0 in 2022, then soared by 40.25% to 12996000.0 in 2023, then fell by 4.79% to 13619000.0 in 2024, then slumped by 181.41% to 38325000.0 in 2025, then fell by 18.24% to 45316000.0 in 2026.
• The last three Cash from Operations figures came in at 45316000.0 (Q1 2026), 38325000.0 (Q4 2025), and 42270000.0 (Q3 2025), per Business Quant data.